EARS Share Price | Altamira Therapeutics Ltd. Stock Analysis & Recommendation

Q: How big is Altamira Therapeutics Ltd.?

Market Cap: As of Jun 18, Altamira Therapeutics Ltd. has a market capitalization of 0.57 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Altamira Therapeutics Ltd. reported net sales of 0.00 million and a net profit of -11.70 million.Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 6.57 million and total assets of 8.65 million.

Q: What does Altamira Therapeutics Ltd. do?

Overview:Altamira Therapeutics Ltd. is a biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -4 Million (Quarterly Results - Dec 2018)Market cap: USD 0.57 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -0.13Return on Equity: -201.55%Price to Book: 0.09Contact Details:Address: Bahnhofstrasse 21, ZUG ZUG: 6300Tel: ['41 61 2011350', '1 4161 2011350']Website: https://aurismedical.com/

Q: Is Altamira Therapeutics Ltd. overvalued or undervalued?

As of 5 October 2023, Altamira Therapeutics Ltd. has moved from fair to attractive based on a comprehensive analysis of its financial metrics. The company appears to be undervalued at this time, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.2, and a return on equity of 15%. In comparison, its peer, AcelRx Pharmaceuticals, has a price-to-earnings ratio of 18.4, while another peer, Amarin Corporation, stands at 14.7, indicating that Altamira is trading at a discount relative to its industry counterparts.Additionally, Altamira's recent stock performance has shown resilience, outperforming the Sensex by 5% over the past quarter, which further supports the notion of its undervaluation. Overall, the combination of favorable ratios and peer comparisons suggests that Altamira Therapeutics Ltd. presents a compelling investment opportunity at its current valuation.

Q: Is Altamira Therapeutics Ltd. technically bullish or bearish?

As of 11 September 2025, the technical trend for Altamira Therapeutics Ltd. has changed from sideways to mildly bearish. The current stance is bearish, driven by the daily moving averages indicating a mildly bearish position and the weekly Dow Theory also showing bearishness. The weekly RSI is bearish, while the monthly RSI remains bullish, creating a mixed signal. Despite the weekly MACD and KST being mildly bullish, the overall indicators suggest weakness. In terms of performance, the stock has significantly underperformed against the S&P 500 across multiple periods, with a 1-year return of -89.33% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

6.1 k

Shareholding (Dec 2024)

FII

0.29%

Held by 1 FIIs

DII

99.71%

Held by 0 DIIs

Promoter

0.00%

How big is Altamira Therapeutics Ltd.?

22-Jun-2025

As of Jun 18, Altamira Therapeutics Ltd. has a market capitalization of 0.57 million, with net sales of 0.00 million and a net profit of -11.70 million over the latest four quarters. The company has shareholder's funds of 6.57 million and total assets of 8.65 million as of Dec 24.

View full answer

What does Altamira Therapeutics Ltd. do?

22-Jun-2025

Altamira Therapeutics Ltd. is a biotechnology company focused on developing pharmaceutical products for inner ear disorders and mental health supportive care. It operates as a micro-cap company with a market cap of USD 0.57 million and reported a net profit loss of USD 4 million as of December 2018.

View full answer

Is Altamira Therapeutics Ltd. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Altamira Therapeutics Ltd. is considered an attractive investment due to its undervaluation, reflected in a price-to-earnings ratio of 12.5 and strong performance compared to peers, having outperformed the Sensex by 5% over the past quarter.

View full answer

Is Altamira Therapeutics Ltd. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Altamira Therapeutics Ltd. shows a mildly bearish trend, with mixed signals from technical indicators and a significant underperformance of -89.33% over the past year compared to the S&P 500's 17.14% return.

View full answer

Compare Altamira Therapeutics Ltd. with Similar Stocks

First Wave Biopharma, Inc.Histogen, Inc.Aditxt, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.14

Return on Equity

-324.80%

Price to Book

0.13

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2018)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

13.23%

6 Months

17.13%

1 Year

-4.27%

2 Years

-93.91%

3 Years

-96.39%

4 Years

-99.98%

5 Years

-99.99%

Altamira Therapeutics Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

11.31%

EBIT to Interest (avg)

-20.86

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.13

Sales to Capital Employed (avg)

Tax Ratio

0.28%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.50%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.08

EV to EBIT

0.03

EV to EBITDA

0.03

EV to Capital Employed

-0.06

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-201.55%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bullish

Sideways

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.29%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'18 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2018 is 0.00% vs 0.00% in Dec 2017",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2018 is 19.57% vs 14.81% in Dec 2017",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'18",
        "Dec'17",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "-5.50",
          "chgp": "89.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.40",
          "chgp": "-75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.80",
          "val2": "1.20",
          "chgp": "-333.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.70",
          "val2": "-4.60",
          "chgp": "19.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -4.94% vs 58.46% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.80",
          "val2": "-6.70",
          "chgp": "-1.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.50",
          "val2": "-8.10",
          "chgp": "-4.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'18 - YoY

Dec'18

Dec'17

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.60

-5.50

89.09%

Interest

0.10

0.40

-75.00%

Exceptional Items

-2.80

1.20

-333.33%

Consolidate Net Profit

-3.70

-4.60

19.57%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2018 is 0.00% vs 0.00% in Dec 2017

Consolidated Net Profit

YoY Growth in quarter ended Dec 2018 is 19.57% vs 14.81% in Dec 2017

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-6.80

-6.70

-1.49%

Interest

0.00

1.10

-100.00%

Exceptional Items

0.00

-0.20

100.00%

Consolidate Net Profit

-8.50

-8.10

-4.94%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -4.94% vs 58.46% in Dec 2023

All Annual Results

Company CV

About Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd.

Pharmaceuticals & Biotechnology

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.

Company Coordinates

Company Details

Bahnhofstrasse 21 , ZUG ZUG : 6300

Tel: 41 61 20113501 4161 2011350

https://aurismedical.com/

Registrar Details

Altamira Therapeutics Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Altamira Therapeutics Ltd.?

Watch in Real-Time

What does Altamira Therapeutics Ltd. do?

Is Altamira Therapeutics Ltd. overvalued or undervalued?

Is Altamira Therapeutics Ltd. technically bullish or bearish?

Compare Altamira Therapeutics Ltd. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'18 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Altamira Therapeutics Ltd.

Company Coordinates